Paper · 42909796

Base editing-mediated exon-specific knockout of glutamine synthetase generates a high-productivity CHO cell line for antibody manufacturing.

Pu T and 9 others. Bioresour Bioprocess, 2026.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. Base editing-mediated exon-specific knockout of glutamine synthetase generates a high-productivity CHO cell line for antibody manufacturing. Papers, record 42909796. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42909796

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: Base editing-mediated exon-specific knockout of glutamine synthetase generates a high-productivity CHO cell line for antibody manufacturing.
Journal: Bioresour Bioprocess
Year: 2026
Publication types: Journal Article
PubMed: https://pubmed.ncbi.nlm.nih.gov/42909796/
DOI: https://doi.org/10.1186/s40643-026-01150-0
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC13694664/
The journal: https://conductscience.org/library/journal-index/101665551
Revised in PubMed: 2026-10-26

Source PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename	ORCID iD
1	Pu T	Tianting
2	Wang C	Chengcheng
3	Lou H	Hui
4	Mi Y	Ye
5	Zhang S	Saiyi
6	Liu S	Siyu
7	Xiao Z	Zhihua
8	Wang Q	Qiyao
9	Liu Q	Qin
10	Liu Y	Yajing	https://orcid.org/0009-0001-0515-2463

Source PubMed

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes it	Agency	Stated by
24HC2820500	Science and Technology Commission of Shanghai Municipality	PubMed
20220701	ECUST-OPM Open Fund	PubMed
222201251721	Fundamental Research Funds for the Central University	PubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References35

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	27,096,365	Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage.	Nature	2016	https://conductscience.org/library/papers/27096365	PubMed
2	39,496,933	Large DNA deletions occur during DNA repair at 20-fold lower frequency for base editors and prime editors than for Cas9 nucleases.	Nat Biomed Eng	2025	https://conductscience.org/library/papers/39496933	PubMed
3	39,047,893	Ala-Cys-Cys-Ala dipeptide dimer alleviates problematic cysteine and cystine levels in media formulations and enhances CHO cell growth and metabolism.	Metab Eng	2024	https://conductscience.org/library/papers/39047893	PubMed
4	38,561,148	Nature as blueprint: Global phenotype engineering of CHO production cells based on a multi-omics comparison with plasma cells.	Metab Eng	2024	https://conductscience.org/library/papers/38561148	PubMed
5	30,323,312	Base editing: precision chemistry on the genome and transcriptome of living cells.	Nat Rev Genet	2018	https://conductscience.org/library/papers/30323312	PubMed
6	26,192,319	Engineered CHO cells for production of diverse, homogeneous glycoproteins.	Nat Biotechnol	2015	https://conductscience.org/library/papers/26192319	PubMed
7	21,804,562	The genomic sequence of the Chinese hamster ovary (CHO)-K1 cell line.	Nat Biotechnol	2011	https://conductscience.org/library/papers/21804562	PubMed
8	37,679,541	Genotoxic effects of base and prime editing in human hematopoietic stem cells.	Nat Biotechnol	2024	https://conductscience.org/library/papers/37679541	PubMed
9	23,287,718	Multiplex genome engineering using CRISPR/Cas systems.	Science	2013	https://conductscience.org/library/papers/23287718	PubMed
10	33,859,400	Generation of recombinant hyperimmune globulins from diverse B-cell repertoires.	Nat Biotechnol	2021	https://conductscience.org/library/papers/33859400	PubMed

1 to 10 of 35

See all 35 references

Cited by0

The papers in our copy of PubMed whose reference list names this one, newest first.

None in this release.

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42909796

GET https://conductscience.org/api/papers/v1/42909796/references?page=2

API reference For AI assistants